N-ethylquinoline-8-sulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-ethylquinoline-8-sulfonamide
• 化学式: C₁₁H₁₂N₂O₂S
• mdl: MFCD03386959
• 分子量: 236.29
• InChiKey: PMSKMKPEFXQPRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Method of Use of Deacetylase Inhibitors
  申请人：Izumo Seigo

  公开号：US20090012066A1

  公开（公告）日：2009-01-08

  The present invention provides methods of treating and/or preventing pathologic cardiac hypertrophy and heart failure comprising administering hydroxamate compounds which are deacetylase inhibitors.

  本发明提供了一种治疗和/或预防病理性心肌肥大和心力衰竭的方法，包括给予去乙酰化酶抑制剂的羟肟酸化合物。
• DEACETYLASE INHIBITORS
  申请人：Remiszewski Stacy William

  公开号：US20080176849A1

  公开（公告）日：2008-07-24

  The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.

  本发明提供了一种羟肟酸化合物，其为去乙酰化酶抑制剂。这些化合物适用于具有抗增殖性质的药物组合物。
• Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US11254652B2

  公开（公告）日：2022-02-22

  Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.

  本文提供了式(I)的无定形和结晶半硫酸盐形式。此外，还提供了包含无定形和结晶半硫酸盐形式的药物组合物、其制造方法及其用于治疗与丙酮酸激酶相关的病症（如丙酮酸激酶缺乏症）的用途。
• PYRUVATE KINASE M2 (PKM2) ACTIVATORS FOR USE IN THERAPY
  申请人：Agios Pharmaceuticals, Inc.

  公开号：EP2658543B1

  公开（公告）日：2019-02-20
• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US20190241523A1

  公开（公告）日：2019-08-08

  Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.